Inclusion Criteria:

- Patients must have histologically documented invasive epithelial ovarian or
extra-ovarian adenocarcinoma

- Patients must have persistent or recurrent disease after standard debulking/staging
surgery and conventional chemotherapy.Prior chemotherapy must have included a
taxane/platinum based regimen

- Patients must have evidence of intraabdominal disease; disease may be measurable or
nonmeasurable

- Patients must have a GOG performance status of 0, 1, or 2, and have a life expectancy
of greater than 3 months

- Patients must have adequate hematologic, renal, cardiac, pulmonary, coagulation, and
hepatic function defined as:

1. WBC> 3,000 ul

2. Granulocytes> 1,500 ul

3. Platelets> 100,000

4. Creatinine clearance (actual or calculated) >80 mg/dl or serum creatinine <2.0

5. Serum transaminases <2.5x upper limits of normal

6. Normal serum bilirubin

7. PT/PTT/INR < 1.5 x institutional ULN

8. Ejection fraction on echocardiogram > 55%

9. O2 saturation > 92%

- Patients must be 19 years or older (as mandated by Alabama state law) and must have
signed informed consent

Exclusion Criteria:

- Patients with epithelial ovarian tumors of low malignant potential (with or without
invasive implants), with ovarian stromal tumors, or with germ cell tumors of the
ovary are ineligible to participate in the study

- Patients with the only site of disease located beyond the abdominal cavity are
ineligible to participate in the study

- Patients who are pregnant or lactating are ineligible to participate in the study

- Patients with a GOG performance status of 3 or 4 are ineligible to participate in the
study

- Patients with active heart disease (characterized by angina, unstable arrhythmia,
congestive heart failure or EF < 55%, pulmonary hypertension), active or chronic
debilitating pulmonary disease (i.e., active pneumonia, severe COPD, pulmonary edema,
O2 saturation < 92%), or coagulation disorders (i.e., bleeding disorders, on
therapeutic anti-coagulants)